Is Granules India Limited a good investment? Granules India Limited (GRANULES.NS) is currently trading at 821.75 INR. Market analysts have a consensus price target of 919.13 INR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 31.62. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Granules India Limited is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is 39.71.
For income investors, Granules India Limited pays a dividend yield of 0.19%. With a payout ratio of 5%, the dividend appears sustainable.
Yes, it pays an annual dividend of 1.75 INR (0.19% yield).
Granules India Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of 26.93.
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
| Year | Total Dividends |
|---|---|
| ▸2027 |
3.50 INR
|
| Sept. 6, 2027 (estimated) | 3.5000 |
| ▸2026 |
1.75 INR
|
| Sept. 4, 2026 | 1.7500 |
| ▸2025 |
1.50 INR
|
| Sept. 6, 2025 | 1.5000 |
| ▸2024 |
1.50 INR
|
| Sept. 5, 2024 | 1.5000 |
| ▸2023 |
1.50 INR
|
| Sept. 8, 2023 | 1.5000 |
| ▸2022 |
1.00 INR
|
| July 30, 2022 | 0.7500 |
| March 10, 2022 | 0.2500 |
| ▸2021 |
1.50 INR
|
| Dec. 12, 2021 | 0.2500 |
| Sept. 3, 2021 | 0.7500 |
| Aug. 26, 2021 | 0.2500 |
| Feb. 27, 2021 | 0.2500 |
| ▸2020 |
1.00 INR
|
| Nov. 19, 2020 | 0.2500 |
| Sept. 12, 2020 | 0.2500 |
| Aug. 16, 2020 | 0.2500 |
| Feb. 20, 2020 | 0.2500 |
| ▸2019 |
1.00 INR
|
| Nov. 21, 2019 | 0.2500 |
| Sept. 28, 2019 | 0.2500 |
| Aug. 29, 2019 | 0.2500 |
| Feb. 28, 2019 | 0.2500 |
| ▸2018 |
1.00 INR
|
| Nov. 28, 2018 | 0.2500 |
| Oct. 5, 2018 | 0.2500 |
| Aug. 22, 2018 | 0.2500 |
| March 10, 2018 | 0.2500 |
| ▸2017 |
1.25 INR
|
| Dec. 9, 2017 | 0.2500 |
| Oct. 28, 2017 | 0.2500 |
| Sept. 13, 2017 | 0.2500 |
| Aug. 2, 2017 | 0.2500 |
| Feb. 27, 2017 | 0.2500 |
| ▸2016 |
0.90 INR
|
| Nov. 25, 2016 | 0.2000 |
| Aug. 23, 2016 | 0.2000 |
| Aug. 3, 2016 | 0.2000 |
| April 1, 2016 | 0.1500 |
| Feb. 27, 2016 | 0.1500 |
| ▸2015 |
0.65 INR
|
| Aug. 5, 2015 | 0.1500 |
| Aug. 4, 2015 | 0.5000 |
| ▸2014 |
3.50 INR
|
| Sept. 27, 2014 | 3.5000 |
| ▸2013 |
2.00 INR
|
| Sept. 19, 2013 | 2.0000 |
| ▸2012 |
2.00 INR
|
| Aug. 1, 2012 | 2.0000 |
| ▸2011 |
1.50 INR
|
| Oct. 12, 2011 | 1.5000 |
| ▸2010 |
1.25 INR
|
| Oct. 27, 2010 | 1.2500 |
| ▸2009 |
2.50 INR
|
| Oct. 26, 2009 | 1.2500 |
| Feb. 1, 2009 | 1.2500 |
| ▸2007 |
1.25 INR
|
| Dec. 24, 2007 | 1.2500 |
| ▸2006 |
1.25 INR
|
| Dec. 21, 2006 | 1.2500 |
| ▸2005 |
1.25 INR
|
| Dec. 1, 2005 | 1.2500 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Granules India Limited | Sep 04, 2026 | Paid | 1.75 INR |
| Split Date | Split Ratio to 1 |
|---|---|
| March 23, 2015 | 10:1 |
Community Discussion